Additional files:
List S1- Read codes for type 2 diabetes
Table S1 - Sensitivity analysis censoring observation periods at time of stopping or changing
therapy.
Table S2 - Baseline characteristics (%) of hypertensive and CVD patients, according to exposure
status
Table S3 - Incident rates of T2DM at different follow-up times, according to hypertension and
CVD diagnosis, for individuals with BMI≤25Kg/m2
1
Read codes for type 2 diabetes - list S1
13B1.00DIABETIC DIET
13L4.11DIABETIC CHILD
1434.00H/O: DIABETES MELLITUS
2BBF.00RETINAL ABNORMALITY - DIABETES RELATED
2G51000FOOT ABNORMALITY - DIABETES RELATED
2G5A.00O/E - RIGHT DIABETIC FOOT AT RISK
2G5B.00O/E - LEFT DIABETIC FOOT AT RISK
3882.00DIABETES WELL BEING QUESTIONNAIRE
3883.00DIABETES TREATMENT SATISFACTION QUESTIONNAIRE
42G4.00GLUCOSE 6-PHOSPHATE DEHYDROG.
42G4.11RED CELL GLUCOSE 6-PHOSPHATE DEHYDROGENASE LEVEL
42G6.00RED CELL GLUCOSE 6-PHOSPHATE DEHYDROGENASE SCREENING TEST
44T..00BLOOD GLUCOSE METHOD
44T..11BLOOD SUGAR METHOD
44T1.00RANDOM BLOOD SUGAR
44T1000RANDOM BLOOD SUGAR NORMAL
44T1100RANDOM BLOOD SUGAR LOW
44T1200RANDOM BLOOD SUGAR RAISED
44T2.00FASTING BLOOD SUGAR
44T3.002 HOURS POST FOOD BLOOD SUGAR
44T3.11POST PRANDIAL BLOOD SUGAR
44T4.00DIP-STICK BLOOD SUGAR
44T5.00LABORATORY BLOOD SUGAR
44T6.00LUNCH TIME BLOOD SUGAR
44T7.00SUPPER TIME BLOOD SUGAR
44T8.00BEDTIME BLOOD SUGAR
44T9.00GLUCOMETER BLOOD SUGAR
44TA.00PLASMA GLUCOSE
44TE.0030 MINUTE BLOOD GLUCOSE LEVEL
44TF.0060 MINUTE BLOOD GLUCOSE LEVEL
44TG.0090 MINUTE BLOOD GLUCOSE LEVEL
44TH.00120 MINUTE BLOOD GLUCOSE LEVEL
44TI.00150 MINUTE BLOOD GLUCOSE LEVEL
44TZ.00BLOOD GLUCOSE METHOD NOS
44U..00BLOOD GLUCOSE RESULT
44U..11BLOOD SUGAR RESULT
44U..12PLASMA GLUCOSE LEVEL
44U1.00BLOOD GLUCOSE 0-1.4 MMOL/L
44U2.00BLOOD GLUCOSE 1.5-2.4 MMOL/L
44U3.00BLOOD GLUCOSE 2.5-4.9 MMOL/L
44U4.00BLOOD GLUCOSE 5-6.9 MMOL/L
44U5.00BLOOD GLUCOSE 7-9.9 MMOL/L
44U6.00BLOOD GLUCOSE 10-13.9 MMOL/L
44U7.002 HOUR POST-PRANDIAL BLOOD GLUCOSE LEVEL
44U8.00BLOOD GLUCOSE NORMAL
44U9.00BLOOD GLUCOSE ABNORMAL
44UZ.00BLOOD GLUCOSE 14+ MMOL/L
44Uz.00BLOOD GLUCOSE RAISED NOS
44V..00GLUCOSE TOLERANCE TEST
44V..11BLOOD GLUCOSE TOLERANCE
44V..12BLOOD SUGAR TOLERANCE
44V1.00GLUCOSE TOLERANCE TEST NORMAL
44V2.00GLUCOSE TOL. TEST IMPAIRED
44V3.00GLUCOSE TOL. TEST DIABETIC
44VZ.00GLUCOSE TOLERANCE TEST NOS
44c1.00SERUM FASTING LIPOPROTEIN LEVEL
44d1.00PLASMA FASTING LIPOPROTEIN LEVEL
44d3.00PLASMA FASTING HDL CHOLESTEROL LEVEL
2
44d5.00PLASMA FASTING LDL CHOLESTEROL LEVEL
44e1.00PLASMA FASTING TRIGLYCERIDE LEVEL
44f..00SERUM GLUCOSE LEVEL
44f0.00SERUM RANDOM GLUCOSE LEVEL
44f1.00SERUM FASTING GLUCOSE LEVEL
44f2.00SERUM 2-HR POST-PRANDIAL GLUCOSE LEVEL
44f3.0030 MINUTE SERUM GLUCOSE LEVEL
44f4.0060 MINUTE SERUM GLUCOSE LEVEL
44f5.0090 MINUTE SERUM GLUCOSE LEVEL
44f6.00120 MINUTE SERUM GLUCOSE LEVEL
44f7.00150 MINUTE SERUM GLUCOSE LEVEL
44g..00PLASMA GLUCOSE LEVEL
44g0.00PLASMA RANDOM GLUCOSE LEVEL
44g1.00PLASMA FASTING GLUCOSE LEVEL
44g2.00PLASMA 2-HR POST-PRANDIAL GLUCOSE LEVEL
44g3.0030 MINUTE PLASMA GLUCOSE LEVEL
44g4.0060 MINUTE PLASMA GLUCOSE LEVEL
44g5.0090 MINUTE PLASMA GLUCOSE LEVEL
44g6.00120 MINUTE PLASMA GLUCOSE LEVEL
44g7.00150 MINUTE PLASMA GLUCOSE LEVEL
44j..00GLUCOSE LOAD TEST
466..00URINE TEST FOR GLUCOSE
4661.00URINE GLUCOSE TEST NOT DONE
4662.00URINE GLUCOSE TEST NEGATIVE
4663.00URINE GLUCOSE TEST = TRACE
4664.00URINE GLUCOSE TEST = +
4665.00URINE GLUCOSE TEST = ++
4666.00URINE GLUCOSE TEST = +++
4667.00URINE GLUCOSE TEST = ++++
4669.00URINE DIPSTICK FOR GLUCOSE
466Z.00URINE GLUCOSE TEST NOS
46S4.00URINE GLUCOSE: CHEM. TITRE
46S4.11GLUCOSE - URINE TITRE
47C2.00FAECES CHROMAT.: GLUCOSE
488..00CSF: GLUCOSE LEVEL
488..11CSF GLUCOSE
4881.00CSF: GLUCOSE NORMAL
4882.00CSF: GLUCOSE DECREASED
488Z.00CSF: GLUCOSE INCREASED
4I39.00FLUID SAMPLE GLUCOSE
4I39.11GLUCOSE IN SAMPLE
66A..00DIABETIC MONITORING
66A1.00INITIAL DIABETIC ASSESSMENT
66A2.00FOLLOW-UP DIABETIC ASSESSMENT
66A3.00DIABETIC ON DIET ONLY
66A4.00DIABETIC ON ORAL TREATMENT
66A5.00DIABETIC ON INSULIN
66A8.00HAS SEEN DIETICIAN - DIABETES
66A9.00UNDERSTANDS DIET - DIABETES
66AA.11INJECTION SITES - DIABETIC
66AC.00BLOOD SUGAR CHARTS
66AD.00FUNDOSCOPY - DIABETIC CHECK
66AG.00DIABETIC DRUG SIDE EFFECTS
66AH.00DIABETIC TREATMENT CHANGED
66AI.00DIABETIC - GOOD CONTROL
66AJ.00DIABETIC - POOR CONTROL
66AJ.11UNSTABLE DIABETES
66AJ100BRITTLE DIABETES
66AJz00DIABETIC - POOR CONTROL NOS
66AK.00DIABETIC - COOPERATIVE PATIENT
3
66AL.00DIABETIC-UNCOOPERATIVE PATIENT
66AM.00DIABETIC - FOLLOW-UP DEFAULT
66AN.00DATE DIABETIC TREATMENT START
66AO.00DATE DIABETIC TREATMENT STOPP.
66AP.00DIABETES: PRACTICE PROGRAMME
66AQ.00DIABETES: SHARED CARE PROGRAMME
66AR.00DIABETES MANAGEMENT PLAN GIVEN
66AS.00DIABETIC ANNUAL REVIEW
66AZ.00DIABETIC MONITORING NOS
66Ag.00INSULIN NEEDLES CHANGED DAILY
66Ah.00INSULIN NEEDLES CHANGED FOR EACH INJECTION
66Ai.00DIABETIC 6 MONTH REVIEW
66Aj.00INSULIN NEEDLES CHANGED LESS THAN ONCE A DAY
66Ak.00DIABETIC MONITORING - LOWER RISK ALBUMIN EXCRETION
66Al.00DIABETIC MONITORING - HIGHER RISK ALBUMIN EXCRETION
68K1.00URINE SCREEN FOR GLUCOSE
8A12.00DIABETIC CRISIS MONITORING
8A13.00DIABETIC STABILISATION
8A17.00SELF MONITORING OF BLOOD GLUCOSE
8A18.00SELF MONITORING OF URINE GLUCOSE
8A19.00SELF MONITORING OF BLOOD AND URINE GLUCOSE
8CA4100PT ADVISED RE DIABETIC DIET
8H2J.00ADMIT DIABETIC EMERGENCY
8H3O.00NON-URGENT DIABETIC ADMISSION
8H4F.00REFERRAL TO DIABETOLOGIST
8H7C.00REFER, DIABETIC LIAISON NURSE
8HHy.00REFERRAL TO DIABETIC REGISTER
8HKE.00DIABETOLOGY D.V. REQUESTED
8HLE.00DIABETOLOGY D.V. DONE
8HME.00LISTED FOR DIABETOLOGY ADMISSN
8HTi.00REFERRAL TO MULTIDISCIPLINARY DIABETIC CLINIC
8HTk.00REFERRAL TO DIABETIC EYE CLINIC ABETIC CLINIC
8HVU.00PRIVATE REFERRAL TO DIABETOLOGIST
9N1Q.00SEEN IN DIABETIC CLINIC
9N1o.00SEEN IN MULTIDISCIPLINARY DIABETIC CLINIC NIC
9N4p.00DID NOT ATTEND DIABETIC RETINOPATHY CLINIC
9NM0.00ATTENDING DIABETES CLINIC
9OL..00DIABETES MONITORING ADMIN.
9OL1.00ATTENDS DIABETES MONITORING
9OL4.00DIABETES MONITORING 1ST LETTER
9OL5.00DIABETES MONITORING 2ND LETTER
9OL6.00DIABETES MONITORING 3RD LETTER
9OL7.00DIABETES MONITOR.VERBAL INVITE
9OL8.00DIABETES MONITOR.PHONE INVITE
9OLA.00DIABETES MONITOR. CHECK DONE
9OLA.11DIABETES MONITORED
9OLZ.00DIABETES MONITORING ADMIN.NOS
C10..00DIABETES MELLITUS
C100011INSULIN DEPENDENT DIABETES MELLITUS
C100111MATURITY ONSET DIABETES
C100112NON-INSULIN DEPENDENT DIABETES MELLITUS
C101.00DIABETES MELLITUS WITH KETOACIDOSIS
C101000DIABETES MELLITUS, JUVENILE TYPE, WITH KETOACIDOSIS
C101100DIABETES MELLITUS, ADULT ONSET, WITH KETOACIDOSIS
C101y00OTHER SPECIFIED DIABETES MELLITUS WITH KETOACIDOSIS
C101z00DIABETES MELLITUS NOS WITH KETOACIDOSIS
C102.00DIABETES MELLITUS WITH HYPEROSMOLAR COMA
C102000DIABETES MELLITUS, JUVENILE TYPE, WITH HYPEROSMOLAR COMA
C102100DIABETES MELLITUS, ADULT ONSET, WITH HYPEROSMOLAR COMA
C102z00DIABETES MELLITUS NOS WITH HYPEROSMOLAR COMA
4
C103.00DIABETES MELLITUS WITH KETOACIDOTIC COMA
C103000DIABETES MELLITUS, JUVENILE TYPE, WITH KETOACIDOTIC COMA
C103y00OTHER SPECIFIED DIABETES MELLITUS WITH COMA
C103z00DIABETES MELLITUS NOS WITH KETOACIDOTIC COMA
C104.00DIABETES MELLITUS WITH RENAL MANIFESTATION
C104.11DIABETIC NEPHROPATHY
C104z00DIABETES MELLITIS WITH NEPHROPATHY NOS
C105.00DIABETES MELLITUS WITH OPHTHALMIC MANIFESTATION
C106.11DIABETIC AMYOTROPHY
C106.12DIABETES MELLITUS WITH NEUROPATHY
C106.13DIABETES MELLITUS WITH POLYNEUROPATHY
C107.11DIABETES MELLITUS WITH GANGRENE
C107.12DIABETES WITH GANGRENE
C107200DIABETES MELLITUS, ADULT WITH GANGRENE
C108.00INSULIN DEPENDENT DIABETES MELLITUS
C108.11IDDM-INSULIN DEPENDENT DIABETES MELLITUS
C108.12TYPE 1 DIABETES MELLITUS
C108400UNSTABLE INSULIN DEPENDANT DIABETES MELLITUS
C108500INSULIN DEPENDENT DIABETES MELLITUS WITH ULCER
C108900INSULIN DEPENDANT DIABETES MATURITY ONSET
C108A00INSULIN-DEPENDENT DIABETES WITHOUT COMPLICATION
C109.00NON-INSULIN-DEPENDENT DIABETES MELLITUS
C109.11NIDDM - NON-INSULIN DEPENDENT DIABETES MELLITUS
C109.12TYPE 2 DIABETES MELLITUS
C10A.00MALNUTRITION-RELATED DIABETES MELLITUS
C10A000MALNUTRITION-RELATED DIABETES MELLITUS WITH COMA
C10A100MALNUTRITION-RELATED DIABETES MELLITUS WITH KETOACIDOSIS
C10B.00DIABETES MELLITUS INDUCED BY STEROIDS
C10EQ00TYPE 1 DIABETES MELLITUS WITH GASTROPARESIS
C10FR00TYPE 2 DIABETES MELLITUS WITH GASTROPARESIS
C10z.00DIABETES MELLITUS WITH UNSPECIFIED COMPLICATION
C11y000STEROID INDUCED DIABETES
C1A..00INSULIN RESISTANCE LITUS WITH GASTROPARESIS
C310.12GLUCOSE-6-PHOSPHATE DEFICIENCY
C310212GLUCOSE-6-PHOSPHATASE DEFICIENCY
C313000GLUCOSE - GALACTOSE INTOLERANCE
C313011MALABSORPTION OF GLUCOSE - GALACTOSE
C313500GLUCOSE INTOLERANCE
C313511MALABSORPTION OF GLUCOSE
C314.11RENAL DIABETES
Cyu2.00[X]DIABETES MELLITUS
Cyu2000[X]OTHER SPECIFIED DIABETES MELLITUS
D102000GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY ANAEMIA
F171100AUTONOMIC NEUROPATHY DUE TO DIABETES
F345000Diabetic mononeuritis multiplex
F35z000DIABETIC MONONEURITIS NOS
F372.00POLYNEUROPATHY IN DIABETES
F372.11DIABETIC POLYNEUROPATHY
F372.12DIABETIC NEUROPATHY
F372000ACUTE PAINFUL DIABETIC NEUROPATHY
F372100CHRONIC PAINFUL DIABETIC NEUROPATHY
F372200ASYMPTOMATIC DIABETIC NEUROPATHY
F381300MYASTHENIC SYNDROME DUE TO DIABETIC AMYOTROPHY
F381311DIABETIC AMYOTROPHY
F3y0.00DIABETIC MONONEUROPATHY
F420.00DIABETIC RETINOPATHY
F420000BACKGROUND DIABETIC RETINOPATHY
F420100PROLIFERATIVE DIABETIC RETINOPATHY
F420200PREPROLIFERATIVE DIABETIC RETINOPATHY
F420300ADVANCED DIABETIC MACULOPATHY
5
F420400DIABETIC MACULOPATHY
F420500ADVANCED DIABETIC RETINAL DISEASE
F420z00DIABETIC RETINOPATHY NOS
F440700DIABETIC IRITIS
F464000DIABETIC CATARACT
G73y000DIABETIC PERIPHERAL ANGIOPATHY
K01x100NEPHROTIC SYNDROME IN DIABETES MELLITUS
L180500PRE-EXISTING DIABETES MELLITUS, INSULIN-DEPENDENT
L180800DIABETES MELLITUS ARISING IN PREGNANCY
L180811GESTATIONAL DIABETES MELLITUS
L180900GESTATIONAL DIABETES MELLITUS
L180X00PRE-EXISTING DIABETES MELLITUS, UNSPECIFIED
L188.00ABNORMAL GLUCOSE TOLERANCE TEST IN PREGNANCY/CHILDB/PUERP
L188.11GTT - GLUCOSE TOLERANCE TEST ABNORMAL IN PREG/CHILDB/PUERP
M037200CELLULITIS IN DIABETIC FOOT
M271000ISCHAEMIC ULCER DIABETIC FOOT
M271100NEUROPATHIC DIABETIC ULCER - FOOT
M271200MIXED DIABETIC ULCER - FOOT
N030000DIABETIC CHEIROARTHROPATHY
N030011DIABETIC CHEIROPATHY
N030100DIABETIC CHARCOT ARTHROPATHY
Q441.00NEONATAL DIABETES MELLITUS
Q44B.00SYNDROME OF INFANT OF MOTHER WITH GESTATIONAL DIABETES
R054200[D]GANGRENE OF TOE IN DIABETIC
R054300[D]WIDESPREAD DIABETIC FOOT GANGRENE
R102.00[D]GLUCOSE TOLERANCE TEST ABNORMAL
R102.12[D]IMPAIRED GLUCOSE TOLERANCE TEST
R105700[D]GLUCOSE, BLOOD LEVEL ABNORMAL
ZV65312[V]DIETARY COUNSELLING IN DIABETES MELLITUS
6
Table S1 - Sensitivity analysis censoring observation periods at time of stopping or changing therapy
Follow up time
(years) Ps [595%]
(N=1,448,993)
Hazard ratio (95% CI)*
STOP
Incident T2DM per 1000 person-years
STOP
CHANGE
Exposed
CHANGE
Unexposed
Exposed
Unexposed
No Hypertension
0-1 yr
2.35 (2.25-2.46)
2.97 (2.86-3.09)
22.07 (21.46-22.70)
8.65 (8.44-8.85)
29.71 (28.99-30.44)
8.91 (8.70-9.11)
1-3 yr
1.62 (1.57-1.68)
1.89 (1.83-1.95)
20.07 (19.63-20.53)
10.60 (10.42-10.77)
23.83 (23.33-24.33)
10.68 (10.49-10.86)
3-5 yr
2.14 (2.06-2.24)
2.33 (2.23-2.43)
23.55 (22.98-24.14)
9.56 (9.33-9.80)
26.31 (25.66-26.98)
9.64 (9.41-9.88)
5-10 yr
10-15 yr
15-20 yr
2.66 (2.55-2.79)
3.31 (2.90-3.78)
4.37 (2.86-6.67)
2.78 (2.65-2.92)
3.09 (2.66-3.59)
4.20 (2.57-6.86)
29.32 (28.70-29.96)
34.17 (32.48-35.96)
44.52 (38.06-52.09)
9.32 (9.06-9.59)
9.31 (8.48-10.21)
11.55 (8.41-15.88)
30.84 (30.10-31.59)
34.59 (32.37-36.96)
45.38 (36.14-56.99)
9.37 (9.11-9.65)
9.34 (8.50-10.26)
11.72 (8.49-16.17)
0-1 yr
1-3 yr
3-5 yr
5-10 yr
10-15 yr
15-20 yr
No CVD
1.08 (1.02-1.14)
0.90 (0.86-0.94)
1.29 (1.22-1.37)
1.64 (1.53-1.75)
2.26 (1.73-2.95)
2.66 (0.89-7.97)
1.31 (1.25-1.38)
1.01 (0.97-1.05)
1.39 (1.31-1.47)
1.62 (1.51-1.75)
2.19 (1.64-2.93)
1.09 (0.22-5.51)
23.11 (19.86-20.96)
23.67 (23.09-24.72)
29.80 (29.01-30.61)
35.80 (34.90-36.73)
41.68 (38.76-44.83)
47.97 (36.25-63.47)
20.40 (19.86-20.96)
24.20 (23.68-24.72)
20.51 (19.82-21.23)
19.25 (18.38-20.17)
18.33 (15.02-22.37)
22.38 (9.31-53.77)
31.15 (30.26-32.07)
27.86 (27.21-28.54)
32.72 (31.83-33.63)
37.02 (35.97-38.10)
42.79 (38.98-46.97)
26.73 (16.12-44.35)
21.28 (20.72-21.85)
24.76 (24.23-25.30)
20.96 (20.24-21.70)
19.70 (18.79-20.65)
19.15 (15.64-23.44)
19.21 (7.21-51.17)
0-1 yr
1-3 yr
3-5 yr
5-10 yr
10-15 yr
15-20 yr
1.99 (1.92-2.06)
1.42 (1.38-1.46)
1.98 (1.91-2.05)
2.49 (2.39-2.59)
3.14 (2.77-3.55)
4.28 (2.83-6.46)
2.49 (2.41-2.58)
1.63 (1.58-1.67)
2.12 (2.04-2.20)
2.53 (2.42-2.64)
2.85 (2.47-3.29)
3.80 (2.31-6.25)
23.47 (22.92-24.03)
21.90 (21.50-22.32)
26.58 (26.04-27.14)
32.31 (31.69-32.94)
35.31 (33.47-37.27)
46.07 (39.13-54.25)
10.74 (10.54-10.95)
12.93 (12.75-13.11)
11.18 (10.95-11.42)
10.56 (10.30-10.83)
10.08 (9.26-10.99)
11.81 (8.70-16.04)
31.35 (30.71-32.00)
25.44 (24.99-25.90)
28.83 (28.23-29.45)
32.99 (32.27-33.72)
33.97 (31.64-36.47)
41.48 (32.47-52.99)
11.04 (10.83-11.25)
13.05 (12.87-13.24)
11.29 (11.06-11.53)
10.62 (10.35-10.89)
10.21 (9.37-11.13)
11.71 (8.55-16.03)
0-1 yr
1-3 yr
3-5 yr
0.83 (0.77-0.91)
0.79 (0.74-0.85)
1.02 (0.92-1.12)
1.01 (0.94-1.09)
0.95 (0.88-1.01)
1.18 (1.07-1.30)
18.85 (17.91-19.83)
20.11 (19.38-20.88)
24.24 (23.31-25.21)
21.05 (20.08-22.07)
23.77 (22.79-24.79)
21.30 (19.83-22.88)
26.31 (25.19-27.48)
25.44 (24.58-26.32)
28.96 (27.86-30.10)
22.84 (21.81-23.91)
24.54 (23.52-25.60)
21.79 (20.25-23.45)
5-10 yr
10-15 yr
15-20 yr
1.40 (1.25-1.57)
2.26 (1.42-3.58)
1.62 (0.35-7.51)
1.51 (1.34-1.71)
2.96 (1.73-5.05)
1.29 (0.24-6.88)
30.22 (29.29-31.17)
37.96 (35.54-40.55)
43.57 (33.90-56.01)
18.73 (16.98-20.66)
14.70 (9.49-22.79)
48.47 (12.12-193.81)
33.45 (32.31-34.63)
42.06 (38.70-45.71)
38.54 (26.04-57.03)
19.71 (17.82-21.81)
13.05 (7.87-21.65)
57.40 (14.35-22.95)
Hypertension
CVD
PS – propensity score; *Final model: adjusted for age and propensity score; CVD – cardiovascular disease; STOP – observation
periods censored at time of statin withdrawn; CHANGE – observation periods censored at time exposure status changed.
7
Table S2 - Baseline characteristics (%) of hypertensive and CVD patients, according to exposure status
Baseline Characteristics
Pscore [5-95%]
BMI>25Kg/m2
Hyperlipidaemia
Abnormal glucose
CVD or Hypertension
Exposed
71.73%
6.33%
1.80%
17.83%
Hypertension
Unexposed
67.04%
4.49%
1.71%
15.88%
CVD
Exposed
63.46%
5.10%
0.93%
33.98%
Unexposed
56.94%
4.99%
1.24%
50.58%
8
Table S3 - Incident rates of T2DM at different follow-up times, according to hypertension and CVD
diagnosis, for individuals with BMI≤25Kg/m2
Statin use
Follow up time (years)
PS [5-95%]
No Hypertension
0-1 yr
1-3 yr
3-5 yr
5-10 yr
10-15 yr
15-20 yr
20-25 yr
Hypertension
0-1 yr
1-3 yr
3-5 yr
5-10 yr
10-15 yr
15-20 yr
20-25 yr
No CVD
0-1 yr
1-3 yr
3-5 yr
5-10 yr
10-15 yr
15-20 yr
20-25 yr
CVD
0-1 yr
1-3 yr
3-5 yr
5-10 yr
10-15 yr
15-20 yr
20-25 yr
Yes
No
Hazard ratio
(95% CI)*
Incident T2DM per 1000
person-years (95% CI)
Incident T2DM per 1000
person-years (95% CI)
1.81 (1.64-2.01)
11.39 (10.62-12.22)
5.20 (4.95-5.47)
1.39 (1.28-1.50)
1.62 (1.47-1.79)
2.12 (1.91-2.35)
2.59 (1.94-3.45)
2.10 (1.00-4.43)
n.e.
11.00 (10.43-11.60)
11.74 (11.04-12.47)
15.06 (14.30-15.87)
17.30 (15.35-19.50)
26.86 (19.78-36.48)
0
6.05 (5.83-6.27)
5.42 (5.14-5.71)
5.15 (4.85-5.48)
5.38 (4.47-6.48)
10.92 (6.69-17.82)
0
1.11 (0.97-1.28)
0.85 (0.76-0.95)
1.11 (0.95-1.29)
1.51 (1.27-1.81)
4.29 (2.11-8.70)
n.e.
n.e.
12.58 (11.49-13.78)
11.99 (11.19-12.85)
14.86 (13.81-16.00)
17.24 (16.07-18.50)
21.19 (17.58-25.54)
21.13 (10.57-42.25)
0
11.05 (10.31-11.85)
12.81 (12.11-13.54)
11.47 (10.52-12.49)
10.47 (9.33-11.75)
7.48 (4.24-13.16)
0
0
1.75 (1.59-1.91)
1.27 (1.18-1.36)
1.55 (1.42-1.70)
2.05 (1.87-2.26)
2.77 (2.10-3.66)
2.53 (1.20-5.34)
n.e.
11.72 (10.99-12.50)
11.21 (10.67-11.76)
12.64 (11.97-13.35)
15.66 (14.89-16.47)
17.82 (15.67-20.27)
26.70 (19.26-37.02)
0
5.79 (5.54-6.05)
6.74 (6.52-6.97)
6.04 (5.76-6.33)
5.63 (5.32-5.95)
5.44 (4.54-6.52)
9.75 (5.88-16.17)
0
0.89 (0.75-1.07)
0.85 (0.73-0.98)
0.99 (0.80-1.22)
1.44 (1.11-1.86)
2.10 (0.83-5.35)
0.37 (0.33-4.04)
n.e.
12.09 (10.81-13.53)
11.80 (10.84-12.85)
13.39 (12.22-14.68)
16.01 (14.85-17.27)
19.04 (16.19-22.38)
23.35 (13.56-40.21)
0
12.86 (11.60-14.26)
14.80 (13.53-16.18)
12.53 (10.75-14.61)
10.40 (8.39-12.90)
9.33 (3.89-22.41)
6.74 (9.49-47.85)
0
9